Develops and commercializes antibody medicines to prevent and treat serious viral infections, including coronavirus, for vulnerable people and healthcare providers.
10-K for FY2025, filed Mar 5, 2026Invivyd, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of monoclonal antibody (“mAb”)…View ↗
On March 22, 2024, we received emergency use authorization (“EUA”) from the U.S. Food and Drug Administration (“FDA”) for PEMGARDA…View ↗
Continued execution of PEMGARDA commercial launch in the U.S. On March 22, 2024, we received an EUA from the FDA for PEMGARDA for the…View ↗
$53.4M
10-K for FY2025, filed Mar 5, 2026
$53.4M ↗
Customers purchase PEMGARDA through third-party specialty distributors, while a small number of infusion centers, healthcare providers and provider institutions buy directly from Invivyd; the product is shipped to care sites, which bill health plans.
10-K for FY2025, filed Mar 5, 2026
No. It lost $52.5M in FY2025.
10-Q for Q3 FY2026, filed Nov 16, 2026
−$33.5MView ↗
8-K, filed Sep 29, 2026
VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and…View ↗
8-K, filed Sep 1, 2026
On August 30, 2026, the Board of Directors (the “Board”) of Invivyd, Inc. (the “Company”) appointed Marc Elia, Chairman of the Board, as…View ↗
8-K, filed Jul 24, 2026
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has until January 19, 2027 to regain compliance with the Minimum Bid…View ↗
8-K, filed Jul 6, 2026
On July 6, 2026, Invivyd, Inc. issued a press release entitled “Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency…View ↗
From a candidate to a commercial launch
The earlier report centered on a coronavirus antibody candidate and described commercialization as a future possibility. The latest report describes PEMGARDA's U.S. commercial launch alongside clinical development of another coronavirus antibody.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 5, 2026Invivyd, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of monoclonal antibody (“mAb”)…View ↗
Continued execution of PEMGARDA commercial launch in the U.S. On March 22, 2024, we received an EUA from the FDA for PEMGARDA for the…View ↗
Advancing VYD2311 through clinical development and regulatory review. Following FDA IND clearance and alignment on our REVOLUTION clinical…View ↗
Broader virus targets
The earlier report discussed influenza among its potential targets. The latest discusses candidates for respiratory syncytial virus and measles alongside its coronavirus programs.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 5, 2026
Competes with AstraZeneca, Roche Pharmaceuticals, Merck, Pfizer Pharmaceuticals, Gilead, Genentech, Moderna, Pfizer-BioNTech, Novavax, GSK, and Sanofi
10-K for FY2025, filed Mar 5, 2026We face competition from segments of the pharmaceutical, biotechnology and other related markets that pursue the development of antibody…View ↗
Loading...